TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36127081
Drug: Ecological Momentary
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ecological Momentary Intervention called SmartSafe in addition to treatment as usual (TAU)
Study: 36127081
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) with monitoring using Ecological Momentary Assessment (EMA)
Study: 34607597
Drug: Free gingival
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free gingival graft (FGG) before implant placement
Study: 34607597
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without FGG before implant placement)
Study: 33197414
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg IV ibuprofen
Study: 35777250
Drug: Heart Rate
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart Rate Variability (HRV) biofeedback treatment including at-home breathing practice
Study: 34165508
Drug: 5 years
Normalized name: Dymadon 5 Years Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 years of zoledronate treatment (4 mg intravenously every 3 months for 2 years, followed by 4 mg intravenously every 6 months for 3 years)
Study: 34165508
Drug: 2 years
Normalized name: Childrens Panadol 5 - 12 Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 years of zoledronate treatment (4 mg intravenously every 3 months for 2 years)
Study: 34165508
Drug: 5 years
Normalized name: Dymadon 5 Years Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 years of zoledronate treatment
Study: 34165508
Drug: 2 years
Normalized name: Childrens Panadol 5 - 12 Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 years of zoledronate treatment
Study: 33272042
Drug: Kaempferia parviflora
Normalized name: Kaempferia galanga root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaempferia parviflora extract (360 mg/day)
Study: 33264337
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 400 mg twice for 1 day or HCQ 200 mg twice daily for 6 days
Study: 36229051
Drug: Guideline-based heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based heart failure treatment alone (Control)
Study: 32152503
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg I.V. every 3 weeks
Study: 33626326
Drug: Topical Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Oxygen Jet Therapy (TOJT)
Study: 36124112
Drug: Topical sesame
Normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sesame oil
Study: 33662054
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of manual and machine-aided cleaning
Study: 35102749
Drug: Belt electrode
Normalized name: ELECTRODE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belt electrode skeletal muscle electrical stimulation (B-SES) combined with conventional physical therapy for 20 minutes each
Study: 35102749
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy for 20 minutes
Study: 33888413
Drug: Insulin‐alone artificial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin‐alone artificial pancreas
Study: 33888413
Drug: Final dual-hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Final dual-hormone system (insulin and pramlintide)
Study: 33888413
Drug: Insulin‐alone arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin‐alone arm
Study: 35837984
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump (with or without CGM)
Study: 32135648
Drug: Chrono-chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chrono-chemotherapy combined with intensity modulated radiotherapy (IMRT)
Study: 32135648
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy combined with intensity modulated radiotherapy (IMRT)
Study: 32135648
Drug: Chrono-chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chrono-chemotherapy combined with IMRT
Study: 32135648
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy combined with IMRT
Study: 33815657
Drug: L-Arginine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Arginine (5 grams per day)
Study: 34082142
Drug: Fresh pomegranate
Normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh pomegranate juice (250 mL twice daily for 2 weeks)
Study: 34831554
Drug: AET +
Normalized name: beta-Aet
DrugBank: HE-2200 (DB06257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AET + ISP (40 g/day, 5 days a week for 8 weeks)
Study: 32056945
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive behavioral therapy (BCBT)
Study: 32532339
Drug: Adolescents with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescents with good oral hygiene
Study: 32013277
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg bolus followed by 0.12 mg/kg/h continuous infusion)
Study: 35266869
Drug: Telephone group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone group (questionnaires administered during a telephone interview)
Study: 32078929
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for dissociative seizures
Study: 33685421
Drug: S-1 monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 monotherapy (80 mg/m2 orally administrated twice daily, at day 1–14, 16 cycles)
Study: 33685421
Drug: Cisplatin with
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin with vinorelbine combination therapy (cisplatin 80 mg/m2 at day 1, vinorelbine 25 mg/m2 at day 1, 8, 4 cycles)
Study: 35382963
Drug: Lidocaine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (2 mg/kg/h)
Study: 35382963
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg/h)
Study: 35382963
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 mcg/kg/h)
Study: 34985236
Drug: End-range Maitland
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-range Maitland mobilization (MG)
Study: 32819981
Drug: Weekly mood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly mood message (control group)
Study: 34490850
Drug: ISC 17536
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISC 17536 (28-day administration)
Study: 34490850
Drug: Placebo (28-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (28-day administration)
Study: 39173098
Drug: pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab plus chemotherapy
Study: 39173098
Drug: placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo plus chemotherapy
Study: 33079463
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g glycidyl ester-rich palm fat
Study: 33079463
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g 2/3-MCPD ester-rich hazelnut oil
Study: 36158840
Drug: Alprostadil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprostadil (40 μg, three times per day)
Study: 36158840
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (5 mg, three times per day)
Study: 32971524
Drug: Silymarin (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (140 mg, 3 times a day)
Study: 34506937
Drug: Capsules containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing 300 mg of standardized extract from B. forficata leaves (2% total flavonoid content)
Study: 35420397
Drug: SARAsp‐Mix (biosimilar
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARAsp‐Mix (biosimilar insulin aspart premix SAR341402 Mix 70/30)
Study: 35420397
Drug: NN‐Mix (originator
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN‐Mix (originator insulin aspart mix 70/30 - NovoMix® 30)
Study: 36401921
Drug: Parenteral vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral vitamin C (100 mg/kg/d for 4 days)
Study: 34493575
Drug: Infarct progression
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infarct progression rate (mL/h)
Study: 35883016
Drug: Script to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Script to explain the delayed antibiotic trial group
Study: 36243576
Drug: tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tranexamic acid 1 g
Study: 36243576
Drug: tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tranexamic acid 0.5 g
Study: 32660667
Drug: Oral quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quinine and intragastric placebo (OQGP)
Study: 32660667
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo and intragastric quinine (OPGQ)
Study: 32660667
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo and intragastric placebo (OPGP)
Study: 32660667
Drug: Oral quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quinine and intragastric quinine (OQGQ)
Study: 39379462
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ICI)
Study: 35357449
Drug: Taxane chemotherapy
Normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane chemotherapy
Study: 32650126
Drug: Management/adjuvant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management/adjuvant therapy recommendations
Study: 36065582
Drug: Outpatient psychiatric
Normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient psychiatric treatment including intensive case management
Study: 33428907
Drug: E4 15
Normalized name: Ethinylestradiol 15 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E4 15 mg/DRSP 3 mg (E4/DRSP)
Study: 33428907
Drug: Ethinylestradiol (EE)
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinylestradiol (EE) 30 µg/levonorgestrel (LNG)
Study: 33428907
Drug: EE 20
Normalized name: AcidFree 200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 20 µg/DRSP 3 mg
Study: 33428907
Drug: EE 30
Normalized name: DAYSEE 30MCG/0.15MG EC TAB 91
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 30 µg/LNG 150 µg
Study: 36223288
Drug: Baerveldt 101-350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baerveldt 101-350 Glaucoma Implant (BGI)
Study: 36339126
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (A)
Study: 35107354
Drug: sMCL augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: sMCL augmentation repair
Study: 34187228
Drug: Lidocaine as
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine as a sodium channel blocker
Study: 32647051
Drug: High-Intensity Interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Interval Training (HIIT) - 4 × 4‐min HIIT (85‐95% peak heart rate) performed thrice weekly for 12 weeks
Study: 33755218
Drug: Chlorhexidine oral
Normalized name: chlorhexidine Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine oral rinse and oropharyngeal spray
Study: 34848169
Drug: Aflibercept 2
Normalized name: ziv-aflibercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 2 mg every 4 weeks (2q4)
Study: 34848169
Drug: Aflibercept 2
Normalized name: ziv-aflibercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 2 mg every 8 weeks after 3 monthly doses (2q8)
Study: 32737183
Drug: Muscimol infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Muscimol infusion into the periaqueductal gray (PAG)
Study: 32737183
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion into the PAG
Study: 34928310
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (intravenous, inhalational, or combined anesthetic agents; n=474)
Study: 34262260
Drug: TPN171H (5-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN171H (5-30 mg dose range)
Study: 34262260
Drug: TPN171H (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN171H (multiple dosing)
Study: 35997620
Drug: mDOT (modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: mDOT (modified directly observed therapy)
Study: 35997620
Drug: Overall HCV
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall HCV treatment
Study: 33564828
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein supplementation (20 g/d soy protein isolate, providing 41 mg/d total isoflavones and 23 mg/d genistein)
Study: 33196579
Drug: Single antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antiplatelet therapy (not explicitly mentioned but implied as control)
Study: 32778008
Drug: Iron-fortified formula
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified formula (12.7 mg/L)
Study: 34174564
Drug: Dietary tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary tryptophan levels of 1.00, 2.00, 3.00, 4.00, 5.00, and 6.00 g/kg
Study: 33676589
Drug: Tocilizumab 6
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 6 mg/kg plus standard care
Study: 33564844
Drug: Heavy resistance
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy resistance training 3 times weekly with whey protein supplementation (HRTW)
Study: 33395498
Drug: Twice-weekly Structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly Structured Interdisciplinary Bedside Rounds (SIBR)
Study: 32620866
Drug: Spa-rehab therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa-rehab therapy
Study: 32620866
Drug: Standard spa
Normalized name: A-Spas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard spa therapy
Study: 36114653
Drug: Ketone monoester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone monoester (27 g per dose, thrice daily for 3 days)
Study: 35330843
Drug: Abacus mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacus mental calculation training (AMC); specific dosage and duration not mentioned.
Study: 36513442
Drug: Moderate daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate daily consumption of cachaça (28 g ethanol/day for men, 14 g for women)
Study: 36513442
Drug: Moderate daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate daily consumption of red wine (28 g ethanol/day for men, 14 g for women)
Study: 32224129
Drug: Tight control
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight control strategy (increased therapy based on fecal calprotectin, serum C-reactive protein, and symptoms)
Study: 32224129
Drug: Deep remission
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep remission (CD endoscopic index of severity scores below 4, no deep ulcerations or steroid treatment for 8 or more weeks)
Study: 33969511
Drug: Medication reconciliation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reconciliation model led by a hospital clinical pharmacist
Study: 34964311
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day plus rifaximin 1,200 mg/day for 3 months
Study: 34146594
Drug: 4-g Alkyrol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-g Alkyrol® (purified shark liver oil) per day for 3 weeks
Study: 35940529
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 50 mg/kg daily from 9 days before HSCT to 30 days after HSCT
Study: 33832645
Drug: Meclon Idra
Normalized name: Idralazina
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclon Idra vaginal gel
Study: 35190840
Drug: Hemoglobin concentration
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin concentration ≤ 10.9 g/dL
Study: 32734919
Drug: Goal Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal Management Training (GMT); 9 sessions, 2 hours each, once weekly (n = 35)
Study: 32734919
Drug: Computerized Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized Cognitive Training (CCT); 9 sessions, 1 hour each, twice weekly (n = 28)
Study: 32745244
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion adjusted by a standard algorithm
Study: 32014046
Drug: Financial incentives
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Financial incentives in addition to interactive management of mobile devices, conditional on achieving antihypertensive goals.
Study: 34851445
Drug: Oral triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral triiodothyronine (T3)
Study: 32875813
Drug: Treatment 1
Normalized name: CVS Acne Treatment 10% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 1 (T1): Vaccinated against ND+IB on days 7 and 14;
Study: 32875813
Drug: Treatment 2
Normalized name: epoch Blemish Treatment 2 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 2 (T2): Vaccinated against ND+IB on days 3 and 7, and IBD on day 14;
Study: 32875813
Drug: Treatment 3
Normalized name: Canesten Clotrimazole Thrush Treatment 3 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 3 (T3): Vaccinated against ND+IB on days 7 and 21, and IBD on day 14;
Study: 34767967
Drug: rTMS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS therapy with individualized MRI guidance
Study: 34767967
Drug: Scalp-targeting rules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp-targeting rules (e.g., Beam F3)
Study: 36471691
Drug: SBRT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBRT + K + M (Stereotactic Body Radiation Therapy with Pembrolizumab and Trametinib)
Study: 36471691
Drug: SBRT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBRT + G (Stereotactic Body Radiation Therapy with Gemcitabine)
Study: 36471691
Drug: SBRT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBRT + G
Study: 32067259
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high baseline TMTV and poor iPET response
Study: 35296289
Drug: Information related
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information related to AstraZeneca's vaccine safety, misinformation, individual health risks, and public health risks.
Study: 33637064
Drug: Sodium hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronic acid (HA) treatment
Study: 32073676
Drug: Beta-blockers withdrawal
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers withdrawal
Study: 32073676
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (beta-blockers continued)
Study: 36159218
Drug: PIPAC in
Normalized name: ZINC OXIDE 6.25 g in 50 g CUTANEOUS CREAM [PIPA SKIN CARE SUN-SATIONAL Mineral Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIPAC in combination with systemic chemotherapy
Study: 35136595
Drug: Universal home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Universal home visits to pregnant women and their spouses (two-monthly visits)
Study: 34840289
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral intervention for anger management (two individual monthly sessions by a psychologist)
Study: 34038558
Drug: Test meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test meal with 300 mL of tea
Study: 33580553
Drug: Comprehensive face‐to‐face
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive face‐to‐face medicine management consultation with an integrated practice pharmacist within seven days of discharge, followed by a consultation with their general practitioner and further pharmacist consultations as needed.
Study: 32746928
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of salient price increases and discounts
Study: 33686630
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl 100 µg
Study: 33686630
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl 200 µg
Study: 33686630
Drug: Oxycodone (control)
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone (control)
Study: 33686630
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (both doses)
Study: 35879705
Drug: 0.075% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075% ropivacaine and 0.5 µg/mL sufentanil